Studier i vævskulturer tyder på, at cellevækst i humane brysttumorer muligvis stimuleres af prolactin.
In placebo-controlled trials with oral RISPERDAL in this population, the incidence of mortality was 4.0% for RISPERDAL-treated patients compared to 3.1% for placebo- treated patients.